OpenAI-funded Biossil buys antibiotic degrader portfolio for up to $91M

OpenAI-funded Biossil is acquiring Theriva's unwanted antibiotic degrader portfolio for up to $91M. The figure is a ceiling; detailed terms were not disclosed.

• Man Sues Claiming ChatGPT Told Him to Stop Paying Rent, Got Evicted2026-11-07
• Data centers become a midterm election flashpoint as voters oppose expansion2026-11-06
• OpenAI closes $11B tranche at $1.25 trillion valuation2026-11-06
• OpenAI launches BioBasicsBench wet-lab agent benchmark2026-11-06
• Hundreds of Artex AI Hacking Tools Exposed Online2026-11-06